Showing results (61-70 of 111) with videos related to

Sort By:
Pageof 12
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 25, 2013
Outcomes in patients age 70 or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignanciesAndrew M Brunner, Haesook T Kim, Erin Coughlin, et al.
Cancer|May 1, 2015
Health care utilization and end-of-life care for older patients with acute myeloid leukemiaAreej R El-Jawahri, Gregory A Abel, David P Steensma, et al.
Blood|June 28, 2019
Multicenter analysis of outcomes in blastic plasmacytoid dendritic cell neoplasm offers a pretargeted therapy benchmarkJustin Taylor, Michael Haddadin, Vivek A Upadhyay, et al.
Blood|May 5, 2018
High <i>NPM1</i>-mutant allele burden at diagnosis predicts unfavorable outcomes in de novo AMLSanjay S Patel, Frank C Kuo, Christopher J Gibson, et al.
JAMA Oncology|September 8, 2017
Development and Validation of a Novel Acute Myeloid Leukemia-Composite Model to Estimate Risks of MortalityMohamed L Sorror, Barry E Storer, Amir T Fathi, et al.
American Journal of Hematology|October 30, 2022
A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromesAmer M Zeidan, Uma Borate, Daniel A Pollyea, et al.
American Journal of Hematology|November 10, 2017
A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemiaDaniel J DeAngelo, Andrew M Brunner, Lillian Werner, et al.
Leukemia|March 30, 2019
Quality of life and mood of older patients with acute myeloid leukemia (AML) receiving intensive and non-intensive chemotherapyAreej El-Jawahri, Gregory A Abel, Lara Traeger, et al.
Ejhaem|July 18, 2022
A nonrandomized phase I and biomarker trial of regorafenib in advanced myeloid malignanciesJoan How, Siyang Ren, Jennifer Lombardi-Story, et al.
Leukemia Research|September 30, 2023
Phase 1 study of JNJ-64619178, a protein arginine methyltransferase 5 inhibitor, in patients with lower-risk myelodysplastic syndromesTamanna Haque, Felix López Cadenas, Blanca Xicoy, et al.
Pageof 12